Drug Approval | July 11, 2025
FDA accepts new drug application for Merck’s Doravirine/Islatravir
The FDA set a target action date of April 28, 2026, under the Prescription Drug User Fee Act
The FDA set a target action date of April 28, 2026, under the Prescription Drug User Fee Act
Xtandi is approved in over 80 countries, including the U.S., EU, and Japan
Takara Bio Europe will distribute MN’s Bioanalysis portfolio in Austria, Belgium, Denmark, France, Germany, Ireland, Luxembourg, Sweden, Switzerland, and the United Kingdom
Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases
Insights are drawn from over 30K+ people across 300+ cities including all metro and tier-1 cities
India’s fertility rate has dropped to 1.9, below the replacement level of 2.1
Lupin and Zentiva sign license and supply agreement for commercializing Certolizumab
Additional data will be presented on a once-weekly oral combination of islatravir and ulonivirine (ISL/ULO) for HIV-1 treatment
The submission is based on data from the STEP UP and STEP UP T2D clinical trials
The first project will focus on developing an AI-based platform for the sterically guided design of bispecific antibodies
Subscribe To Our Newsletter & Stay Updated
